Cargando…
Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure
Hepatitis B virus (HBV) is one of the most significant hepatocarcinogens. The ultimate goal of anti-HBV treatment is to prevent the development of hepatocellular carcinoma (HCC). During the last two decades, with the use of currently available anti-HBV therapies (lamivudine, entecavir and tenofovir...
Autores principales: | Shinn, Brianna J, Martin, Aaron, Coben, Robert M, Conn, Mitchell I, Prieto, Jorge, Kroop, Howard, DiMarino, Anthony J, Hann, Hie-Won |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354125/ https://www.ncbi.nlm.nih.gov/pubmed/30705719 http://dx.doi.org/10.4254/wjh.v11.i1.65 |
Ejemplares similares
-
Update Treatment for HBV Infection and Persistent Risk for Hepatocellular Carcinoma: Prospect for an HBV Cure
por: Yoo, Joseph, et al.
Publicado: (2018) -
Hepatitis B virus pathogenesis: Fresh insights into hepatitis B virus RNA
por: Sekiba, Kazuma, et al.
Publicado: (2018) -
Challenge of managing hepatitis B virus and hepatitis C virus infections in resource-limited settings
por: Said, Zeinab Nabil Ahmed, et al.
Publicado: (2022) -
Impact of hepatitis B virus infection on hepatic metabolic signaling pathway
por: Shi, Yi-Xian, et al.
Publicado: (2016) -
Risk of hepatocellular carcinoma after hepatitis C virus cure
por: Luna-Cuadros, Maria Alejandra, et al.
Publicado: (2022)